Kohlberg Kravis Roberts is a prominent global investment firm that specializes in managing a diverse range of alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, as well as hedge funds through strategic partnerships. Founded in 1976, the firm focuses on generating attractive investment returns by employing a disciplined and patient investment approach. KKR is committed to driving growth and value creation in its portfolio companies while aligning its interests with those of its investment partners. The firm also provides comprehensive human resources services to enhance operational effectiveness. With a presence in multiple countries, including India and Japan, KKR continues to leverage its extensive expertise and industry knowledge to deliver value across its investment strategies.
9 West 57th Street, Suite 4200, New York, New York 10019, US
Taski Ahmed
Principal, KKR Prisma
Mustapha Angwa
CEO
Anne Arlinghaus
Managing Director
Joe Bae
Co-President and Co-COO
David Biener
VP Finance
Todd Builione
Member, President of KKR Credit
Jim Burns
Partner
Daniel Celeghin
Managing Director, Client and Partner Group
Spencer Chavez
Principal
Mukul Chawla
Partner, Head of Asia Pacific Growth Equity
Steve Codispoti
Director, Finance
Benjamin Conner
Managing Director
Kendra Decious
Director, Finance
Patrick Devine
Director
Brian Dillard
Partner and Head of Asia Credit
Brandon Donnenfeld
Director
Jamison Ely
Director
Mark Ennis
Director
Len Fliegel
Director
Marco Fontana
Managing Director
Brandon Freiman
Partner, Head of North American Infrastructure
Philipp Freise
Co-Head of European Private Equity
Terence Gallagher
Managing Director
Travers Garvin
Director, Public Affairs
Felix Gernburd
Managing Director
Alan Grant
Principal, KKR Capstone
Elizabeth Hammond
Managing Director
Chris Harrington
Partner
Erich Heintzen
Director
Jill Henn
Managing Director, Human Capital
Sota Horiuchi
Principal, Private Equity
Jeff Van Horn
Managing Director, Credit
Paul Horwood
CFO, European Operations
Mark Hunt
Director, Capital Management Group
Johannes P. Huth
Managing Director and Head of KKR EMEA
Hisao Iijima
Principal, Private Equity
Gary H. Jacobs
Managing Director, Capital Management Group
Zhen Ji
Managing Director, China
Franziska Kayser
Managing Director
Kazuyuki Kido
Managing Director
Philip Kim
Managing Director
Thomas Kim
Managing Director and Global Risk Manager
Daan Knottenbelt
Partner
Rie Koike
Principal, Client and Partner Group
Joan Lacagnina
Managing Director, Finance
Jeremiah Lane
Principal
Dashiell Lane
Director, Energy and Infrastructure
David Lang
Partner
Joshua Lederman
Principal and Associate
Elissa Leechawengwongs
Principal, Private Equity
Vincent Letteri
Managing Director, TMT Growth Equity
Robert Lewin
Partner
Xiang Li
Managing Director, Private Equity
Frances Lim
Managing Director, Global Macro and Asset Allocation and Portfolio Mgt of Strategic Partnerships
Max Lin
Partner and Director, Private Equity
Lucy Liu
Director, Client and Partner Group
Ming Lu
Partner and Co-Head of Asia Private Equity Business
Rony Ma
Director
Blaine MacDougald
Director and Co-head of Credit Research, Credit
Emily Mason
Principal, KKR Prisma
Kyle Matter
Director
Patrick Mattson
Managing Director
Kevin McMahon
Managing Director
Hilary McNamara
Director, Business Operations
David McNellis
Managing Director, Global Macro and Asset Allocation
Henry McVey
Partner and Head of Global Macro and Asset Allocation, CIO of KKR Balance Sheet
Ken Mehlman
Partner and Global Head of Public Affairs; Co-head KKR Global Impact
Jimmy Miele
Principal
George Mueller
Managing Director
Katherine T. B. de Mul
Director, Operations and Client Services
Narender Nanchary
Principal, Hedge Funds
Sanjay Nayar
CEO
William Needham
Managing Director
Sean Nelson
Director
Lesley Nurse
Director, Client and Partner Group
Scott Nuttall
Co-CEO
Ted Oberwager
Principal, Private Equity
Christian Ollig
Director, Private Equity
Timotheus Osnabrug
Director, Private Equity
John Park
Director, Private Equity
Chung Ho Park
Director, Private Equity
Vishal Patel
Managing Director
Clayton Perry
Managing Director, Client and Partner Group
Daniel Pietrzak
Partner
Samuel Plotner
Director
Jaka Prasetya
Partner
Sharath Reddy
Director, Credit
John Reed
Director, Credit
Janice Cook Roberts
Director, Client and Partner Group
Paul Roberts
Managing Director, KKR Prisma
James Rudy
Director, Principal Activities
Jean -Pierre Saad
Director, Private Equity
Matt Salem
Partner and Head of RE Credit
Kaveh Samie
Managing Director, Client and Partner Group
Richard Sarnoff
Managing Director
Kugan Sathiyanandarajah
Managing Director and Head of Healthcare Strategic Growth in Europe
Jeffrey Schachter
Managing Director
Lucian Schönefelder
Partner
Vance Serchuk
Managing Director, Americas Private Equity, Industrials Team
Stephen Shanley
Partner
Peggy Shaughnessy
Managing Director, Business Operations
Blake Shorthouse
Managing Director
Rob Siegel
Director, Information Technology
Tashwinder Singh
Director, Capital Markets
Duncan Smith
Principal, Credit
Pete Stavros
Co-Head of Global Private Equity
Chris Sun
Partner, Private Equity
Karan Swani
Director, Private Equity
Marta Szczerba
Director
Waldemar Szlezak
Managing Director
Weiyu Tan
Managing Director
Nate Taylor
Co-Head of Americas Private Equity
Paige Thacher
Principal
Cade Thompson
Partner, Capital Markets
Gaurav Trehan
Head of Asia Private Equity
Cecilio Velasco
Managing Director
Steven Wang
Principal, Private Equity
Douglas Watt
Managing Director
Joshua T. Weisenbeck
Partner
Dave Welsh
Partner and Head of Technology Growth Equity
Ryan L.G. Wilson
Managing Director
Alisa A. Wood
Partner
Angela Yang
Principal, Credit
Annie Yangeksakul
Principal, Hedge Funds
Eiji Yatagawa
Partner
Past deals in Medical Devices
Karo Healthcare
Acquisition in 2025
Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.
HealthCare Global Enterprises
Acquisition in 2025
HealthCare Global Enterprises is a cancer center is a center which offers complete diagnosis and treatment radiation, surgical and medical oncology services under one a single roof. cancer care services. The also operate fertility clinics, multi-specialty hospitals providing cardiology, neurology, orthopedics, gastroenterology, urology, pulmonary and critical care services. Its service offerings comprise of the clinical lab, diagnosis, robotic surgery, bone marrow transplantation, and radiation oncology.
HealthCare Global
Acquisition in 2025
HealthCare Global they focuses on cancer care, tertiary care, infertility treatment, advanced screening, and diagnostics.
Henry Schein
Post in 2025
Henry Schein is a leading provider of healthcare products and services, primarily catering to office-based dental, medical, and animal health practitioners. The company operates through two main segments: healthcare distribution and technology & value-added services. In its healthcare distribution segment, Henry Schein combines global dental and medical businesses to distribute a wide range of consumable products, small equipment, laboratory supplies, and vitamins. The technology and value-added services segment focuses on offering practice management software and other technological solutions that enhance operational efficiency for healthcare professionals. With a strong emphasis on leveraging a network of people and technology, Henry Schein aims to support practitioners in delivering high-quality care.
Cortex
Private Equity Round in 2023
Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market.
Precipart
Private Equity Round in 2023
Precipart is a medical device company that offers motion control systems, ceramic injection molding, and micro manufacturing.
Bausch Health Companies
Post in 2023
Bausch Health Companies Inc. is a global specialty pharmaceutical, consumer health, and medical device company headquartered in Laval, Canada. It develops, manufactures, and markets a diverse range of products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four key segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment focuses on vision care, surgical, consumer, and ophthalmology products. The Salix segment is dedicated to gastroenterology products, while Ortho Dermatologics specializes in dermatological solutions. The Diversified Products segment includes pharmaceutical offerings in neurology and other therapeutic classes, alongside generic and dental products. Bausch Health is recognized as a market leader in consumer vision care in various regions, including India and China, and ranks among the top vision care companies in the United States.
Industrial Physics
Acquisition in 2023
Industrial Physics is manufacturer of test, measurement and inspection equipment focused on the food and beverage, metal cans, flexible packaging, paper and plastics, paint and coatings, medical device, materials testing and consumer electronics markets
Clinisupplies
Acquisition in 2022
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.
Bettcher Industries
Acquisition in 2021
Bettcher Industries is an ISO 9001-certified manufacturing company established in 1944, known for its innovative equipment designed for the food processing, foodservice, industrial, and medical sectors. With over seventy years of experience, Bettcher Industries develops a wide range of products, including trimmers, weighing systems, food safety equipment, batter breading machines, pneumatic shears, electric gyro knives, and sharpening tools. These products enable food processing industries to efficiently transform raw materials into marketable food items while also providing solutions for industrial and medical applications that alleviate the discomfort associated with manual systems. The company serves a diverse global customer base, emphasizing quality and innovation in its manufacturing processes.
Sapphiros
Series A in 2021
Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.
PHC Holdings
Private Equity Round in 2021
PHC Holdings Corp is a global corporation dedicated to the development, manufacture, and sale of healthcare devices and services. Leveraging its expertise in consumer electronics and appliances, the company focuses on creating innovative healthcare and research technologies. By integrating ideas and advancements from its extensive network of industrial and consumer products, PHC Holdings aims to address significant global challenges in health and wellness. The company is recognized for delivering a comprehensive range of biomedical products that enhance healthcare delivery and improve patient outcomes.
Paige
Series C in 2021
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.
Clinisupplies
Acquisition in 2020
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.
J B Chemical & Pharmaceuticals
Acquisition in 2020
Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally. Today, JBCPL exports to over 30 countries across the world and earns more than half its revenue from its international business. JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. JBCPL has its headquarters in India’s financial capital, Mumbai. With a domestic sales force of 1,000 people, 17 internationally approved state of the art manufacturing units, a Research and Development Centre, and subsidiaries abroad, the organisation is continually enhancing value for its shareholders. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.
Hetian Group
Acquisition in 2018
HeTian is a professional hospital management company specialized in operating and investing in integrated health care service providers. HeTian currently operates seven award-winning hospitals and health care centers focused on underserved Chinese cities. The company’s vision is to improve access to quality health care services by building a network of primary medical care providers supported by modern health care management best practices.
Ajax Health
Series B in 2018
Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.
Hyperion Materials & Technologies
Acquisition in 2017
Hyperion Materials & Technologies is a global provider of advanced materials, specializing in cemented carbide, diamond, and cubic boron nitride solutions. The company manufactures metal cutting and drilling equipment tailored for various industries, including aerospace, automotive, electronics, and medical sectors. By developing innovative tungsten carbide powders and wear-resistant tools, Hyperion enables its customers to enhance their business performance in demanding applications. The focus on hard and super-hard materials positions the company as a key player in the production of effective and durable components and tools.
EchoNous
Series B in 2017
EchoNous, Inc. is a medical device company based in Redmond, Washington, focused on developing advanced ultrasound systems that enhance bladder and kidney care. Incorporated in 2015, EchoNous specializes in point-of-care ultrasound (POCUS) applications, utilizing artificial intelligence and machine learning to improve diagnostic accuracy and efficiency. Its product lineup includes KOSMOS for cardiothoracic assessments, Vein for ultrasound-guided peripheral IV placement, and Uscan, an AI-driven tool for bladder assessment. The company aims to address common healthcare challenges by providing miniaturized ultrasound devices that streamline clinical workflows and enhance patient care, ultimately saving time and reducing costs for healthcare providers.
Laser Clinics Australia
Acquisition in 2017
Laser Clinics Australia now has clinics in over 80 convenient locations throughout Australia with many more to come. Since their first clinic opened in 2008 Laser Clinics Australia has established a dominant position in the cosmetic clinic market. They has carved a new niche, creating an exceptionally strong brand and large customer base through the supply of affordable, accessible and reliable cosmetic treatments.
Ajax Health
Series A in 2017
Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.
AcuFocus
Private Equity Round in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
Spirox
Series C in 2016
Spirox, Inc., based in Menlo Park, California, is a medical device company focused on improving the quality of life for patients with nasal obstruction, particularly those suffering from nasal valve collapse (NVC). Formerly known as Nasoform, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive treatment option for this common yet often undertreated condition. The implant addresses weakened lateral wall cartilage, a significant contributor to nasal airway obstruction. Founded in 2011, Spirox aims to complete product development, secure marketing authorization in the United States, and initiate commercialization efforts to make their innovative solution available to patients. As of July 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.
EchoNous
Series A in 2015
EchoNous, Inc. is a medical device company based in Redmond, Washington, focused on developing advanced ultrasound systems that enhance bladder and kidney care. Incorporated in 2015, EchoNous specializes in point-of-care ultrasound (POCUS) applications, utilizing artificial intelligence and machine learning to improve diagnostic accuracy and efficiency. Its product lineup includes KOSMOS for cardiothoracic assessments, Vein for ultrasound-guided peripheral IV placement, and Uscan, an AI-driven tool for bladder assessment. The company aims to address common healthcare challenges by providing miniaturized ultrasound devices that streamline clinical workflows and enhance patient care, ultimately saving time and reducing costs for healthcare providers.
PHC Holdings
Funding Round in 2014
PHC Holdings Corp is a global corporation dedicated to the development, manufacture, and sale of healthcare devices and services. Leveraging its expertise in consumer electronics and appliances, the company focuses on creating innovative healthcare and research technologies. By integrating ideas and advancements from its extensive network of industrial and consumer products, PHC Holdings aims to address significant global challenges in health and wellness. The company is recognized for delivering a comprehensive range of biomedical products that enhance healthcare delivery and improve patient outcomes.
Gland Pharma
Private Equity Round in 2013
Gland Pharma Limited is a manufacturer and marketer specializing in injectable-focused generic liquid parenteral products. Established in 1978 in Hyderabad, India, the company has developed a diverse portfolio of key molecules, including heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections. Its product range spans various therapeutic categories such as anti-infectives, anesthetics, anti-coagulants, oncology, and more. Gland Pharma is particularly recognized for its expertise in small volume parenterals and has pioneered heparin technology in India, becoming a leader in glycosaminoglycans. The company primarily serves regulated markets, with a significant share of its business coming from the United States, Canada, Europe, and Australia. In addition to its manufacturing capabilities, Gland Pharma offers contract development and manufacturing services to global partners, reinforcing its commitment to high-quality injectable products. As of October 2017, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Apollo Hospitals
Post in 2013
Apollo Hospitals is widely recognized as the pioneer of private healthcare in India, and was the country’s first corporate hospital. The Apollo Hospitals Group, which started as a 150-bed hospital and today, operates 9200 beds across 64 hospitals. A forerunner in integrated healthcare, Apollo has a robust presence across the healthcare spectrum. The Group has emerged as the foremost integrated healthcare provider in Asia, with mature group companies that specialize in insurance, pharmacy, consultancy, clinics and many such key touch points of the ecosystem. The Apollo Group has touched the lives of over 45 million patients, from 121 countries.
Accellent
Acquisition in 2005
Accellent provide manufacturing services to the medical device industry in the cardiology, endoscopy and orthopaedic markets. Accellent has broad capabilities in precision component fabrication, finished device assembly, engineering support services and complete supply chain management. These capabilities enhance customers’ speed to market and return on investment by allowing companies to refocus internal resources more efficiently.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.